Evidence map›Paper›PMID 25224277›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2014

Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas.

Sichen Li, Reshmi Chowdhury, Fei Liu, Arthur P Chou, Tie Li, Reema R Mody, Jerry J Lou, Weidong Chen, Jean Reiss, Horacio Soto and 7 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. The Role of Mir-148a in Cancer.Journal of Cancer · 2016
    Review
  18. The Cancer Genome Atlas Analysis Predicts MicroRNA for Targeting Cancer Growth and Vascularization in Glioblastoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2015
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 2 countries.

Sichen LiDepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Reshmi ChowdhuryDepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Fei LiuDepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Arthur P ChouDepartment of Neurosurgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Tie LiDepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Reema R ModyDepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Jerry J LouDepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Weidong ChenDepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Jean ReissDepartment of Pathology & Lab Med-Clinical Labs, UCLA Health System, University of California Los Angeles, Los Angeles, California.
Horacio SotoDepartment of Neurosurgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Robert PrinsDepartment of Neurosurgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Linda M LiauDepartment of Neurosurgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Paul S MischelLaboratory of Molecular Pathology, Ludwig Institute for Cancer Research, University of California San Diego, La Jolla, California.
Phioanh L NghiemphuDepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
William H YongDepartment of Pathology & Lab Med-Clinical Labs, UCLA Health System, University of California Los Angeles, Los Angeles, California.
Timothy F CloughesyDepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Albert LaiDepartment of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California. albertlai@mednet.ucla.edu.
University of California, Los Angeles · USUCLA Health · USLudwig Cancer Research · BE

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZACK, JEROME A. · 1991 to 2018
$39.9M
Investigation of tumor suppressive miR-148a in IDH mutant gliomasR01CA179071 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LAI, ALBERT · 2014 to 2018
$1.6M
Genome-wide promoter methylation profiling of gliomaK08CA124479 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LAI, ALBERT · 2008 to 2012
$790k
NCI NIH HHS K08 CA124479NCI NIH HHS K08CA124479NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA179071NCI NIH HHS R01CA179071NIAID NIH HHS P30 AI028697
6 · The paper itself

Abstract

purposeIDH1/2-mutant gliomas harbor a distinct glioma-CpG island methylation phenotype (G-CIMP) that may promote the initiation and progression of secondary pathway gliomas by silencing tumor-suppressive genes. The potential role of tumor-suppressive microRNAs (miRNA; miR) in this process is not understood. EXPERIMENTAL

designTo identify potential tumor-suppressive miRNA hypermethylated in glioma, the methylation profiles of IDH1/2(WT) gliomas (n = 11) and IDH1(MUT) glioma (n = 20) were compared by using massively parallel reduced representation bisulfite sequencing (RRBS). The methylation status of selected miRNA was validated by using targeted bisulfite sequencing (BiSEQ) in a large cohort of glioma tissue samples including 219 IDH1(WT) and 72 IDH1/2(MUT) samples. The expression of selected miRNAs was determined by using the TaqMan qPCR. Functional analyses of miR148a were conducted and target genes were identified.

resultsWe identify miR148a as a novel, G-CIMP-associated miRNA whose methylation is tightly correlated with IDH1 mutation and associated with improved survival in patients with malignant glioma. We confirm that downregulation of miR148a can occur via DNA methylation. We demonstrate that IDH1 mutation provides a mechanism of miR148a methylation and downregulation, and that restoration of miR148a reduced tumorigenic properties of glioma cells, possibly by targeting DNMT1.

conclusionsWe identify miR148a as a novel G-CIMP-associated miRNA, and provide results suggesting that miR148a restoration may have therapeutic implications.

Indexed as

CpG IslandsDNA MethylationGene SilencingMutationAnimalsAntineoplastic AgentsBrain NeoplasmsCell Line, TumorCluster AnalysisCohort StudiesDisease Models, AnimalGene Expression ProfilingGene Expression Regulation, NeoplasticGliomaHeterograftsHumansAntineoplastic AgentsIDH1 protein, humanIsocitrate DehydrogenaseMicroRNAsMIRN148 microRNA, human

Identifiers

PMID25224277
PMCPMC4233178
OpenAlexW2159815038

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.